IVERIC bio Inc. (ISEE)
NASDAQ: ISEE
· Real-Time Price · USD
39.95
0.15 (0.38%)
At close: Jul 10, 2023, 10:00 PM
IVERIC bio Revenue Breakdown
| Period Ending | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|
| Active Pharmaceutical Ingredient Transfers Revenue | 754K | 18.21M | 5.02M | 883K |
| Active Pharmaceutical Ingredient Transfers Revenue Growth | -95.86% | +262.79% | +468.52% | n/a |
| Joint Operating Committee Revenue Revenue | 131K | 19K | 24K | 38.37M |
| Joint Operating Committee Revenue Revenue Growth | +589.47% | -20.83% | -99.94% | n/a |
| Licensing Revenue | 152.91M | 22.94M | 38.08M | 2M |
| Licensing Revenue Growth | +566.66% | -39.77% | +1800.35% | n/a |
| Research And Development Activities Revenue | 56.18M | 9.74M | 8.38M | n/a |
| Research And Development Activities Revenue Growth | +476.74% | +16.27% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 31.76M | 27.13M | 17.55M | 16.11M | 12.11M | 8M | 6.65M | 6.72M | 8.32M | 8.02M | 6.64M | 6.29M | 5M | 6.28M | 4.67M | 5.2M | 5.48M | 5.67M | 5.97M | 6.33M | 5.64M | 6.91M | 7.06M | 8.55M | 13.16M | 12.97M | 12.02M | 10.49M | 14.7M | 12.07M | 10.41M | 11.96M | 9.58M |
| Selling, General, and Administrative Revenue Growth | +17.06% | +54.63% | +8.93% | +32.96% | +51.39% | +20.35% | -1.04% | -19.27% | +3.74% | +20.76% | +5.63% | +25.83% | -20.35% | +34.25% | -10.08% | -5.16% | -3.28% | -5.04% | -5.75% | +12.17% | -18.34% | -2.07% | -17.46% | -35.01% | +1.47% | +7.86% | +14.63% | -28.63% | +21.80% | +15.89% | -12.94% | +24.78% | n/a |
| Research and Development Revenue | 42.08M | 35.84M | 24.97M | 33.65M | 22.56M | 25.1M | 17.93M | 23.49M | 18.55M | 17.47M | 18.84M | 12.72M | 13.75M | 11.57M | 10.38M | 10.01M | 7.68M | 16.13M | 9.41M | 8.52M | 7.69M | 7.95M | 10.71M | 15.66M | 31.98M | 59.41M | 50.85M | 48.26M | 37.77M | 33.92M | 40.48M | 32.06M | 24.56M |
| Research and Development Revenue Growth | +17.42% | +43.55% | -25.80% | +49.16% | -10.12% | +39.93% | -23.64% | +26.63% | +6.16% | -7.26% | +48.12% | -7.49% | +18.87% | +11.40% | +3.74% | +30.24% | -52.35% | +71.45% | +10.46% | +10.80% | -3.27% | -25.79% | -31.62% | -51.04% | -46.17% | +16.82% | +5.37% | +27.78% | +11.36% | -16.21% | +26.26% | +30.55% | n/a |